| 33.94 0.87 (2.63%) | 06-17 11:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.98  |
1-year : | 49.04 |
| Resists | First : | 35.95 |
Second : | 41.98 |
| Pivot price | 32.92  |
|||
| Supports | First : | 32.81 |
Second : | 30.87 |
| MAs | MA(5) : | 33.08 |
MA(20) : | 33.02 |
| MA(100) : | 35.7 |
MA(250) : | 26.92 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 45.9 |
D(3) : | 43.3 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 43.72 | Low : | 6.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ COGT ] has closed below upper band by 39.4%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.62 - 33.79 | 33.79 - 33.92 |
| Low: | 32.03 - 32.2 | 32.2 - 32.34 |
| Close: | 32.79 - 33.09 | 33.09 - 33.32 |
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Sun, 14 Jun 2026
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha
Sat, 13 Jun 2026
Cogent Biosciences (COGT) Is Up 6.7% After Positive PEAK Trial Data and FDA Priority Review - What's Changed - Sahm
Sat, 13 Jun 2026
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow - Seeking Alpha
Thu, 11 Jun 2026
Director for Cogent Biosciences (NASDAQ: COGT) granted 17,901 stock options - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 171 (M) |
| Shares Float | 161 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 112.1 (%) |
| Shares Short | 11,520 (K) |
| Shares Short P.Month | 11,750 (K) |
| EPS | -2.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.18 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -85.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -285 (M) |
| Levered Free Cash Flow | -167 (M) |
| PE Ratio | -15.43 |
| PEG Ratio | 0 |
| Price to Book value | 10.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|